|
1
|
Sidwell RW, Robins RK and Hillyard IW:
Ribavirin: An antiviral agent. Pharmacol Ther. 6:123–416. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shepherd J, Jones J, Hartwell D, Davidson
P, Price A and Waugh N: Interferon alpha (pegylated and
non-pegylated) and ribavirin for the treatment of mild chronic
hepatitis C: A systematic review and economic evaluation. Health
Technol Assess. 111–205. (iii)2007.PubMed/NCBI
|
|
3
|
De la Cruz-Hernandez E, Medina-Franco JL,
Trujillo J, Chavez-Blanco A, Dominguez-Gomez G, Perez-Cardenas E,
Gonzalez-Fierro A, Taja-Chayeb L and Dueñas-Gonzalez A: Ribavirin
as a tri-targeted antitumor repositioned drug. Oncol Rep.
33:2384–2392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Assouline S, Culjkovic B, Cocolakis E,
Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH
Jr and Borden KL: Molecular targeting of the oncogene eIF4E in
acute myeloid leukemia (AML): A proof-of-principle clinical trial
with ribavirin. Blood. 114:257–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kentsis A, Topisirovic I, Culjkovic B,
Shao L and Borden KL: Ribavirin suppresses eIF4E-mediated oncogenic
transformation by physical mimicry of the 7-methyl guanosine mRNA
cap. Proc Natl Acad Sci USA. 101:18105–18110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borroto-Esoda K, Myrick F, Feng J, Jeffrey
J and Furman P: In vitro combination of amdoxovir and the inosine
monophosphate dehydrogenase inhibitors mycophenolic acid and
ribavirin demonstrates potent activity against wild-type and
drug-resistant variants of human immunodeficiency virus type 1.
Antimicrob Agents Chemother. 48:4387–4394. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Casaos J, Huq S, Lott T, Felder R, Choi J,
Gorelick N, Peters M, Xia Y, Maxwell R, Zhao T, et al: Ribavirin as
a potential therapeutic for atypical teratoid/rhabdoid tumors.
Oncotarget. 9:8054–8067. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Volpin F, Casaos J, Sesen J, Mangraviti A,
Choi J, Gorelick N, Frikeche J, Lott T, Felder R, Scotland SJ, et
al: Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma
therapeutic. Oncogene. 36:3037–3047. 2007. View Article : Google Scholar
|
|
9
|
Béguelin W, Popovic R, Teater M, Jiang Y,
Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Wang L, et al: EZH2
is required for germinal center formation and somatic EZH2
mutations promote lymphoid transformation. Cancer Cell. 23:677–692.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sasaki D, Imaizumi Y, Hasegawa H, Osaka A,
Tsukasaki K, Choi YL, Mano H, Marquez VE, Hayashi T, Yanagihara K,
et al: Overexpression of Enhancer of zeste homolog 2 with
trimethylation of lysine 27 on histone H3 in adult T-cell
leukemia/lymphoma as a target for epigenetic therapy.
Haematologica. 96:712–719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Soumyanarayanan U and Dymock BW: Recently
discovered EZH2 and EHMT2 (G9a) inhibitors. Future Med Chem.
8:1635–1654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peveling-Oberhag J, Arcaini L, Bankov K,
Zeuzem S and Herrmann E: The anti-lymphoma activity of antiviral
therapy in HCV-associated B-cell non-Hodgkin lymphomas: A
meta-analysis. J Viral Hepat. 23:536–544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pettersson F, Yau C, Dobocan MC,
Culjkovic-Kraljacic B, Retrouvey H, Puckett R, Flores LM, Krop IE,
Rousseau C, Cocolakis E, et al: Ribavirin treatment effects on
breast cancers overexpressing eIF4E, a biomarker with prognostic
specificity for luminal B-type breast cancer. Clin Cancer Res.
17:2874–2884. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pettersson F, Del Rincon SV, Emond A, Huor
B, Ngan E, Ng J, Dobocan MC, Siegel PM and Miller WH Jr: Genetic
and pharmacologic inhibition of eIF4E reduces breast cancer cell
migration, invasion, and metastasis. Cancer Res. 75:1102–1112.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma S, Baksi R and Agarwal M:
Repositioning of anti-viral drugs as therapy for cervical cancer.
Pharmacol Rep. 68:983–989. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xi C, Wang L, Yu J, Ye H, Cao L and Gong
Z: Inhibition of eukaryotic translation initiation factor 4E is
effective against chemo-resistance in colon and cervical cancer.
Biochem Biophys Res Commun. 503:2286–2292. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Richard SM and Martinez Marignac VL:
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by
metformin and ribavirin and differences in response to
mitochondrial glutaminase inhibition. J Cancer Res Ther.
11:336–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kosaka T, Nagamatsu G, Saito S, Oya M,
Suda T and Horimoto K: Identification of drug candidate against
prostate cancer from the aspect of somatic cell reprogramming.
Cancer Sci. 104:1017–1026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Culjkovic B and Borden KL: Understanding
and targeting the eukaryotic translation initiation factor eIF4E in
head and neck cancer. J Oncol 2009. 9816792009.
|
|
20
|
Attar-Schneider O, Drucker L and Gottfried
M: Migration and epithelial-to-mesenchymal transition of lung
cancer can be targeted via translation initiation factors eIF4E and
eIF4GI. Lab Invest. 96:1004–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan K, Culjkovic B, Amri A and Borden KL:
Ribavirin targets eIF4E dependent Akt survival signaling. Biochem
Biophys Res Commun. 375:341–345. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Volpon L, Osborne MJ, Zahreddine H, Romeo
AA and Borden KL: Conformational changes induced in the eukaryotic
translation initiation factor eIF4E by a clinically relevant
inhibitor, ribavirin triphosphate. Biochem Biophys Res Commun.
434:614–619. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Borden KL and Culjkovic-Kraljacic B:
Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and
beyond? Leuk Lymphoma. 51:1805–1815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Culjkovic-Kraljacic B, Fernando TM,
Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M,
Zahreddine H, Goldstein RL, et al: Combinatorial targeting of
nuclear export and translation of RNA inhibits aggressive B-cell
lymphomas. Blood. 127:858–868. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rutherford SC, Stewart EN, Chen Z,
Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard
JP and Cerchietti L: The eIF4E inhibitor ribavirin as a potential
antilymphoma therapeutic: Early clinical data. Leuk Lymphoma.
59:256–258. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dunn GP, Koebel CM and Schreiber RD:
Interferons, immunity and cancer immunoediting. Nat Rev Immunol.
6:836–848. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferrantini M, Capone I and Belardelli F:
Interferon-alpha and cancer: Mechanisms of action and new
perspectives of clinical use. Biochimie. 89:884–893. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Belardelli F, Ferrantini M, Proietti E and
Kirkwood JM: Interferon-alpha in tumor immunity and immunotherapy.
Cytokine Growth Factor Rev. 13:119–134. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rotman Y, Noureddin M, Feld JJ, Guedj J,
Witthaus M, Han H, Park YJ, Park SH, Heller T, Ghany MG, et al:
Effect of ribavirin on viral kinetics and liver gene expression in
chronic hepatitis C. Gut. 63:161–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun WH, Pabon C, Alsayed Y, Huang PP,
Jandeska S, Uddin S, Platanias LC and Rosen ST: Interferon-alpha
resistance in a cutaneous T-cell lymphoma cell line is associated
with lack of STAT1 expression. Blood. 91:570–576. 1998.PubMed/NCBI
|
|
31
|
Sugaya M, Tokura Y, Hamada T, Tsuboi R,
Moroi Y, Nakahara T, Amano M, Ishida S, Watanabe D, Tani M, et al:
Phase II study of i.v. interferon-gamma in Japanese patients with
mycosis fungoides. J Dermatol. 41:50–56. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kyvernitakis A, Duvic M, Mahale P and
Torres HA: Interferon-based treatment for patients with mycosis
fungoides and hepatitis C virus infection: A case series. Am J Clin
Dermatol. 15:451–456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Care MA, Westhead DR and Tooze RM: Gene
expression meta-analysis reveals immune response convergence on the
IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in
lymphoma. Genome Med. 7:962015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Woo J, Kim HY, Byun BJ, Chae CH, Lee JY,
Ryu SY, Park WK, Cho H and Choi G: Biological evaluation of
tanshindiols as EZH2 histone methyltransferase inhibitors. Bioorg
Med Chem Lett. 24:2486–2492. 2014. View Article : Google Scholar : PubMed/NCBI
|
